N/A N=713 Xenform Postmarket Surveillance Study
Pelvic Organ Prolapse
Primary: Number of Participants With Success at 36 Months — 191; 390 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=782 Prevention of Malaria in HIV-uninfected Pregnant Women and Infants
Malaria
Primary: Number of Participants Who Deliver With a Composite Adverse Birth Outcome — 60; 54 Participants
Phase 2 N=40 A Trial of Standard Chemotherapy With Metformin (vs Placebo) in Women With Metastatic Breast Cancer
Metastatic Breast Cancer
Primary: Progression Free Survival. — 5.4; 6.3 months — p=0.71
N/A N=31 rTMS in the Treatment of PTSD
Post-traumatic Stress Disorder (PTSD)
Primary: Clinician-Administered PTSD Scale for DSM-IV (CAPS-IV) — 59.80; 74.00; 65.12 units on a scale — p=0.046
N/A N=4 Amnion-Chorion Allograft Barrier Used for Root Surface and Guided Tissue Regeneration
Periodontal Diseases
Primary: Probing Depth Change — 4.22 millimeter
Phase 3 N=605 Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients
Mesothelioma
Primary: Overall Survival (OS) — 18.07; 14.09 Months — p=0.0020
Phase 2 N=420 A Study to Compare a New Drug for Type 2 Diabetes to Placebo and to a Treatment Already Available for Type 2 Diabetes
Diabetes Mellitus, Type 2
Primary: Change From Baseline in Hemoglobin A1c (HbA1c) at Week 12 — -1.07; -1.09; -1.44; -1.33 percentage of HbA1c — p=0.459
Phase 2 N=144 CAP: Doxazosin in the Treatment of Co-Occurring PTSD and Alcohol Use Disorders
Posttraumatic Stress Disorder · Alcohol Use Disorders
Primary: Clinician Administered PTSD Scale — 34.2; 32.5 score on a scale
Phase 3 N=236 Evaluate the Efficacy and Safety of ON101 Cream for the Treatment of Chronic Diabetic Foot Ulcers
Diabetic Foot
Primary: Number of Participants With Complete Ulcer Closure — 74; 40 Participants
N/A N=342 Sick-Day Protocol to Improve Outcomes in Chronic Kidney Disease
Safety Issues · Chronic Kidney Diseases
Primary: Change in Renal Function From Baseline to Study Completion; — 0.01; 0.02 mg/dL
N/A N=24 Role of Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) on Inflammation and Lipids
Metabolic Syndrome
Primary: Interleukin-6 (IL-6) — 0.96; 1.01; 0.99 pg/mL — p=0.33
N/A N=11 Mindfulness in Adolescents With Obesity
Mindfulness · Usual Care
Primary: Number of Sessions Attended by Participant — 85 percentage of all sessions attended
Phase 2 N=20 EPI-743 for Metabolism or Mitochondrial Disorders
Mitochondrial Disease · Neurology · Myopathy
Primary: Newcastle Paediatric Mitochondrial Disease Scale (NPMDS) Part I-III, Baseline — 23.9; 20.4 Units on a scale
Phase 2 N=19 Mifepristone Effects on Glucose Intolerance in Obese/Overweight Adults
Endocrine Disease · Diabetes
Primary: Change in Insulin Sensitivity Index — 1.49; 1.41 min-1·μU·ml-1 — p=0.60
N/A N=38 The Effect of Biomechanical Scapular Mobilization With Movement and Motor Learning
Shoulder Impingement Syndrome
Primary: Visual Analogue Scale — 4.2; 0.9 score on a scale